Claim Amendments

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-10. (Canceled)

Claim 11. (Currently Amended) Piperazine A piperazine benzothiazole derivatives according to compound having formula I

$$R^{1}$$
 S CN $N-R$ (I)

as well as its tautomers, its geometrical isomers, its optically active forms as <u>an</u>

<u>enantiomer enantiomers</u>, <u>a diastereomer diastereomers</u> and <u>its as a racemate forms</u>, as well as pharmaceutically acceptable salts thereof, wherein

R is selected from the group comprising or consisting of hydrogen, C₁-C₆-alkyl, C₁-C₆-alkyl aryl, heteroaryl, C₁-C₆-alkyl heteroaryl, C₂-C₆-alkenyl, C₂-C₆-alkenyl aryl, C₂-C₆-alkenyl heteroaryl, C₂-C₆-alkynyl, C₂-C₆-alkynyl aryl, C₂-C₆-alkynyl heteroaryl, C₃-C₈-cycloalkyl, heterocycloalkyl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl, C₁-C₆-alkyl carboxy, acyl, C₁-C₆-alkyl acyl, acyloxy, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl alkoxy, alkoxycarbonyl, C₁-C₆-alkyl alkoxycarbonyl, aminocarbonyl, C₁-C₆-alkyl amino, C₁-C₆-alkyl acylamino, ureido, C₁-C₆-alkyl ureido, amino, C₁-C₆-alkyl amino, sulfonyloxy, C₁-C₆-alkyl sulfonyloxy, sulfonyl, C₁-C₆-alkyl sulfonyl, sulfonyl, sulfonyl, sulfonyl, sulfonylamino, and C₁-C₆-alkyl sulfonylamino, and C₁-C₆-alkyl sulfonylamino, and C₁-C₆-alkyl sulfonylamino, and mixtures thereof;

 R^1 is selected from the group comprising or consisting of H, halogen, cyano, nitro, amino, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_6 -alkyl-aryl, aryl or heteroaryl, C_1 - C_6 -alkyl-heteroaryl, -C(O)- OR^2 , -C(O)- R^2 , -C(O)- NR^2R^2 ', and $-(SO_2)R^2$ and mixtures thereof, with

R² and R² being independently selected from the group comprising or consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, C₁-C₆-alkyl aryl, C₁-C₆-alkyl heteroaryl and combinations mixtures thereof; and n is an integer from 0 to 3.

Claim 12. (Currently Amended) The A piperazine benzothiazole derivative according to claim 11, wherein R¹ is hydrogen.

Claim 13. (Currently Amended) <u>The A piperazine benzothiazole derivative</u> according to claim 11, wherein R is selected from the group consisting of hydrogen, C₁-C₃ alkyl, aminocarbonyl, C₁-C₆-alkyl alkoxycarbonyl, C₁-C₆-alkyl alkoxycarbonyl, and C₁-C₆-alkyl aminocarbonyl and mixtures thereof.

Claim 14. (Currently Amended) <u>The</u> A piperazine benzothiazole derivative according to claim 13, wherein R is H, or C_1 - C_3 alkyl, in particular a methyl or an ethyl moiety, or C_1 - C_6 -alkyl alkoxy.

Claim 15. (Currently Amended) <u>The</u> A piperazine benzothiazole derivative according to claim 11, wherein n is 1.

- Claim 16. (Currently Amended) The A piperazine benzothiazole derivative according to claim 11 selected from the following group consisting of:
- 1,3-benzothiazol-2-yl[2-({4-[(4-methylpiperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl]acetonitrile,
- 1,3-benzothiazol-2-yl[2-({4-[(4-benzyl-piperazin-1-yl)methyl]-benzyl}oxy)pyrimidin-4-yl]acetonitrile,
- 1,3-benzothiazol-2-yl(2-{[4-(piperazin-1-ylmethyl)benzyl]oxy}pyrimidin-4-yl)acetonitrile,
- 1,3-benzothiazol-2-yl[2-({4-[(4-formylpiperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl]acetonitrile,
- [2-({4-[(4-acetylpiperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl](1,3-benzothiazol-2-yl)acetonitrile,
- (3H-Benzothiazol-2-ylidene)-{2-[4-(4-[1,2,4]oxadiazol-3-ylmethyl-piperazin-1-ylmethyl)-benzyloxy]-pyrimidin-4-yl}-acetonitrile,
- 4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazine-1-carboxylic acid methyl ester,
- 2-[4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazin-1-yl]-acetamide,
- (2-{4-[4-(2-Amino-acetyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-(3H-benzothiazol-2-ylidene)-acetonitrile,
- [4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazin-1-yl]-acetic acid methyl ester,

Appln No. 10/485,484 Reply to Office Action of October 26, 2006

(3H-Benzothiazol-2-ylidene)-(2-{4-[4-(2-methoxy-ethyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-acetonitrile,

4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazine-1-carboxylic acid dimethylamide,

(3H-Benzothiazol-2-ylidene)-{2-[4-(4-ethyl-piperazin-1-ylmethyl)-benzyloxy]-pyrimidin-4-yl}-acetonitrile, and

(3H-Benzothiazol-2-ylidene)-(2-{4-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-acetonitrile.

Claims 17 to 19. (Canceled)

Claim 20. (New) A pharmaceutical composition, comprising:

a therapeutically effective amount of the piperazine benzothiazole compound according to claim 11 with a pharmaceutically carrier.

Claim 21. (New) A method of treating cerebral ischemic disorders or CNS disorders, comprising:

administering the pharmaceutical composition according to claim 20 to a subject in need of treatment.

Claim 22. (New) A process for the preparation of a piperazine benzothiazole compound claimed in claim 11, comprising:

Appln No. 10/511,438 Reply to the Office Action of October 26, 2006

reacting a pyrimidinylbenzothiazole compound of formula (IV)

$$\mathbb{R}^{1-\frac{1}{U}} \xrightarrow{\mathbb{N}} \mathbb{C} \mathbb{N}$$

with a piperazinyl alcohol compound of formula (V)

$$N-R$$
 $N-R$ V

wherein R, R¹ and n are as defined in claim 11, thereby preparing the piperazine benzothiazole compound of claim 11.